Snowden Capital Advisors’s Adicet Bio ACET Stock Holding History

Snowden Capital Advisors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-94	Closed	-$26K	–	1036
2021 Q4	$26K	Buy	+94	New	+$16.1K	﹤0.01%	1230

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Snowden Capital Advisors's ACET Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Adicet Bio (ACET) in Q1 2022, closing a stake of 94 shares — an estimated $26K sold.

Snowden Capital Advisors first reported a position in ACET in Q4 2021 and held it in 1 quarter. The position peaked at $26K in Q4 2021. 87 funds tracked by Wall St. Rank hold ACET as of Q1 2022.

Snowden Capital Advisors reported no remaining Adicet Bio position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 94 Adicet Bio shares in Q1 2022, an estimated $26K.
Snowden Capital Advisors first reported a position in Adicet Bio in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Adicet Bio position peaked at $26K in Q4 2021.
87 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.